
    
      The study is a open-blind, randomised trial that will be conducted in asymptomatic
      professionals working in areas of high exposure and high risk of transmission of SARS-COV-2.

      After obtaining fully informed consent, the investigator will recruit workers in areas of
      high exposure and high risk of transmission of SARS-COV-2.

      Participants will be divided into 2 groups:

        -  Hydroxychloroquine (HCQ) = 400mg twice on day 1, 400mg/day on day 2, 3, 4, and 5
           followed by 400mg once every 05 days, for the next 7 weeks associated with 20 milligrams
           twice on day of active zinc for 45 consecutive days;

        -  Ivermectin (IVM) = Dosage guidelines based on participant body weight, once on day for 2
           consecutive days, This dose schedule should be repeated every 14 days for 45 days
           associated with 20 milligrams twice on day of active zinc.
    
  